生物学杂志

• 研究报告 •    下一篇

肝癌中EPHA3受体SAM结构域缺失突变体的发现

  

  1. 1. 同济大学附属杨浦医院 上海市杨浦区中心医院,上海 200090;2. 第二军医大学 肿瘤研究所,上海 200433
  • 出版日期:2017-02-18 发布日期:2017-02-18
  • 通讯作者: 陈霞,助理研究员,博士,主要研究方向为肿瘤转移机制,E-mail: chenxxchen@hotmail.com
  • 基金资助:
    国家自然科学基金青年项目(81101574)

Identification of a novel SAM-deletion mutation of the receptor tyrosine kinase EPHA3 in liver cancer

  1. 1. Shanghai Yangpu District Central Hospital, Yangpu Hospital, Tongji University, Shanghai 200090;2. The International Joint Cancer Institute, The Second Military Medical University, Shanghai 200433, China
  • Online:2017-02-18 Published:2017-02-18

摘要: 酪氨酸蛋白激酶受体(RTKs)具有调节细胞生长、分化和迁移的能力,是一类多功能的跨膜糖蛋白。EPH受体家族蛋白高度保守,成员众多,是RTKs中最大的一个分支。大量的研究表明,EPH家族蛋白不仅在胚胎发育过程中具有调节细胞间黏附或排斥、细胞迁移、轴突导向以及血管形成等多方面作用,并且在一些恶性肿瘤的血管生成、肿瘤转移与侵袭等肿瘤的发生发展及预后过程中也发挥着重要的调节作用。在研究EPHA3受体对肝癌转移的作用过程中,发现Epha3在肝癌组织中具有一种新的突变体,该突变体在其胞内部分缺失了96 bp并提前终止翻译而缺少SAM结构域,推测其可能在肝癌的发生发展过程中起调控作用。

关键词: EPHA3, 突变, 肿瘤, 酪氨酸激酶受体

Abstract: tEPHA3 is a member of the ephrin receptor family, which composes the largest subgroup of the known receptor tyrosine kinases. EPH receptors and their ephrin ligands are essential for a variety of biological processes such as cell adhesions and repulsion, cell migration, axon guidance and angiogenesis et al, and they are implicated in cancer metastasis and invasion. In this study, a novel mutation of Epha3 gene was unexpectedly discovered in liver cancer, where its cytoplasmic SAM domain was incomplete. It is supposedly a novel way for Epha3 regulation in liver cancer.

Key words: EPHA3, tumour, cancer, receptor tyrosine kinase